Drug intelligence / Profile preview

Clotinab

Development stage: Phase 2
Lead developer: ISU Abxis
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Clotinab (ISU301) is a biosimilar version of abciximab, a glycoprotein (GP) IIb/IIIa receptor antagonist. It is a chimeric monoclonal antibody fragment (Fab) that inhibits platelet aggregation by binding to the integrin alpha-IIb/beta-3 (GP IIb/IIIa) receptor on activated platelets, thereby preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Developed by ISU Abxis, Clotinab is primarily indicated for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention (PCI) and for the treatment of acute myocardial infarction (AMI) and unstable angina. The drug is produced using Chinese hamster ovary (CHO) cell culture technology and is administered via intravenous injection.

Brand names: Clotinab
Other names: abciximababciximab biosimilarclopidogrel-ISU Abxis Co., Ltd.-acute myocardial infarction

Targets

GPIIb/IIIa (Integrin alpha-IIb/beta-3)

Beyond the preview

Go deeper on Clotinab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clotinab.

Explore the full profile